Obstetric cholestasis with elevated gamma glutamyl transpeptidase: Incidence, presentation and treatment

Background:  Obstetric cholestasis (OC) may cause severe pruritus in the mother and lead to fetal distress and stillbirth. The etiology of OC is multifactorial, but includes inherited dysfunction of bile canalicular transporters. One of these, multidrug resistant protein 3 (MDR3), a phospholipid tra...

Full description

Saved in:
Bibliographic Details
Published inJournal of gastroenterology and hepatology Vol. 18; no. 11; pp. 1283 - 1286
Main Authors MILKIEWICZ, PIOTR, GALLAGHER, RUTH, CHAMBERS, JENNY, EGGINGTON, ENID, WEAVER, JUDITH, ELIAS, ELWYN
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Science Pty 01.11.2003
Blackwell Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background:  Obstetric cholestasis (OC) may cause severe pruritus in the mother and lead to fetal distress and stillbirth. The etiology of OC is multifactorial, but includes inherited dysfunction of bile canalicular transporters. One of these, multidrug resistant protein 3 (MDR3), a phospholipid transporter, when dysfunctional is associated with elevated levels of gamma glutamyl transpeptidase (GGT). The aim of the present study was to assess the incidence of OC associated with elevated GGT. We compared the natural history of a cholestatic pregnancy and the efficacy of ursodeoxycholic acid (URSO) in OC patients grouped according to a normal or raised GGT level. Methods:  Eighty‐one patients with OC were analyzed. OC was diagnosed in patients with pruritus and elevated serum bile acids (SBA). Fifty‐seven consenting volunteer patients (70%) were treated with URSO. Results:  Elevated GGT at presentation was found in 21 patients (30%) and was associated with significantly higher serum levels of aspartate transaminase (AST), bilirubin (BIL) and SBA. OC presented at approximately the same gestation week in both groups of patients. In patients not treated with URSO, liver function tests (LFT) showed no significant change from the time of diagnosis to delivery. Patients from both groups responded to URSO with significant improvement in their AST and alanine aminotransferase (ALT) levels, but SBA fell significantly only in the normal GGT group. Conclusions:  An elevated GGT occurs in less than one‐third of patients with OC in the UK and, when present, is associated with greater impairment of LFT, but no difference in gestational age at onset. Treatment with URSO appears to be safe and significantly improves LFT in patients with OC, with the exception of SBA in the high GGT group.
Bibliography:ark:/67375/WNG-XN3LN0HF-0
istex:4A0891E7059C5A88CC0FC7382BF67964AC41272D
ArticleID:JGH3171
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0815-9319
1440-1746
DOI:10.1046/j.1440-1746.2003.03171.x